Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Comment by Benedictuson Mar 05, 2019 7:37pm
160 Views
Post# 29446825

RE:Expected financing finally out of the way

RE:Expected financing finally out of the wayI've been monitoring LDS from the sidelines and been waiting to see this pp announcement. 
I understand that the mj sector is initially focused on top line growth numbers but with lds bloated share count getting even more bloated, can someone more versed in what lds is putting together walk me through how profits will ever filter down to the bottom line with roughly 160M shs outstanding? I am currently neither bulllish nor bearish on lds. It does appear that momentum is picking up speed and so after the pp closing I could possibly see a run toward the 1 area or even old highs on news of cannastrip/reveur success but I cannot get past how the sp will be severely hamstrung by share count. Now if cannastrips prove to be a runaway success and demand goes nuts for them, well then that would change things completely but I never lose sight of the fact that there are hundreds of products in dispensaries and clear winner products are still in early vying stages. Have the distillate margins improved any since drop in price late last year? Cerrainly would welcome any insights from some of you more up to speed on the co.
Bullboard Posts